Eventide Asset Management LLC Acquires 4,146 Shares of Amgen Inc. $AMGN

Eventide Asset Management LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 17.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,372 shares of the medical research company’s stock after acquiring an additional 4,146 shares during the period. Eventide Asset Management LLC’s holdings in Amgen were worth $9,320,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Arax Advisory Partners grew its holdings in Amgen by 88.2% during the 4th quarter. Arax Advisory Partners now owns 5,710 shares of the medical research company’s stock worth $1,869,000 after acquiring an additional 2,676 shares in the last quarter. Ariadne Wealth Management LP grew its holdings in Amgen by 8.7% during the 4th quarter. Ariadne Wealth Management LP now owns 922 shares of the medical research company’s stock worth $302,000 after acquiring an additional 74 shares in the last quarter. Brown Advisory Inc. grew its holdings in Amgen by 1.4% during the 4th quarter. Brown Advisory Inc. now owns 122,302 shares of the medical research company’s stock worth $40,031,000 after acquiring an additional 1,704 shares in the last quarter. Bollard Group LLC grew its holdings in Amgen by 0.8% during the 4th quarter. Bollard Group LLC now owns 3,961 shares of the medical research company’s stock worth $1,296,000 after acquiring an additional 30 shares in the last quarter. Finally, Atlas Capital Advisors Inc. bought a new position in Amgen during the 4th quarter worth about $2,201,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on AMGN. Leerink Partners reiterated a “market perform” rating and set a $355.00 target price on shares of Amgen in a report on Thursday, March 5th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Sunday. Royal Bank Of Canada increased their target price on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Wells Fargo & Company increased their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Finally, Truist Financial increased their target price on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus price target of $354.12.

Amgen Price Performance

NASDAQ:AMGN opened at $355.20 on Monday. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The stock has a market capitalization of $191.70 billion, a P/E ratio of 24.72, a P/E/G ratio of 3.56 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The company’s 50-day simple moving average is $340.97 and its 200-day simple moving average is $345.80.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the business earned $4.90 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.